Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.

Journal of comparative effectiveness research - 1 May 2016

Swallow Elyse, Kelley Caroline, Signorovitch James, Wygant Gail, McPhee Fiona

Abstract excerpt

AIM: To compare daclatasvir + asunaprevir (DCV + ASV) versus sofosbuvir/ledipasvir (SOF/LDV) for hepatitis C virus genotype 1b in Japanese patients without NS5A polymorphisms at L31 and Y93H. PATIENTS & METHODS: All Phase III trials of SOF/LDV and DCV + ASV conducted in Japan were included. To adjust for cross-trial differences, DCV + ASV patients were weighted to match reported SOF/LDV summary baseline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Fluorenes

Share to Imidazoles

Share to Isoquinolines

Share to Pyrrolidines

Share to Sofosbuvir

Source

Identifiers

PMID: 26793987
DOI: 10.2217/cer.15.69

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.PMID 26793987Read ↗

Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.Semantic proximity Read ↗

Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan.Semantic proximity Read ↗

Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.Semantic proximity Read ↗

Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.Semantic proximity Read ↗

Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.Semantic proximity Read ↗

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.Semantic proximity Read ↗

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.Semantic proximity Read ↗

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.Semantic proximity Read ↗

Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1.Semantic proximity Read ↗

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Daclatasvir + asunaprevir: first global approval.Semantic proximity Read ↗

NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.